Dear Colleagues, The IMCA-CAT beamline at the Advanced Photon Source (APS) is continuing to operate and collect crystallography data during the current restricted-access operations at Argonne National Laboratory. Experiments are limited to (1) critical research related to COVID-19 or (2) critical proprietary research related to drug development.
All pharmaceutical companies and research entities conducting either COVID-19 related research or critical research in drug discovery are invited to inquire about access to IMCA-CAT for beam time. All experiments must be either remote access or mail-in. IMCA-CAT is committed to accelerating drug discovery through synchrotron-based structural biology research. The insertion device beamline is optimized for delivering exceptional quality data, collecting data at high-throughput rates, and ensuring data security for proprietary experiments. Streamlined pathways for establishing proprietary agreements have been implemented for new industrial users to begin conducting experiments without delay. For more information about accessing IMCA-CAT, please contact Dr. Lisa Keefe (email is keefe [at] imca-cat.org). Work safely and stay healthy, Lisa Keefe ------------------------------------------------------------------------------------------------------------------------- Lisa J Keefe, PhD Director IMCA-CAT Industrial Macromolecular Crystallography Association - Collaborative Access Team 630.252.0544 • Sector 17 @ Advanced Photon Source, Argonne National Laboratory Vice President for Advancing Therapeutics Hauptman-Woodward Medical Research Institute Interim CEO American Crystallographic Association ------------------------------------------------------------------------------------------------------------------------- ######################################################################## To unsubscribe from the CCP4BB list, click the following link: https://www.jiscmail.ac.uk/cgi-bin/webadmin?SUBED1=CCP4BB&A=1
